Inovio Pharmaceuticals (INO) +105% Climb Over 30 Days as FDA Decision Nears
Key Takeaways
- INO shares climbed roughly 105% over the past 30 days, rising from about $0.66 to around $1.36.
- The rebound followed a sharp late-July selloff tied to a $20 million equity offering that diluted existing shareholders.
- Investor attention remains centered on the FDA decision for lead candidate INO-3107 in recurrent respiratory papillomatosis (RRP), with a PDUFA target action date of October 30, 2026.
- Second-quarter 2026 results showed a narrower net loss of $0.07 per share, and Jefferies upgraded the stock to Buy with a $3.00 price target.
- The stock remains highly volatile and well below its 52-week high, reflecting binary event risk ahead of the FDA decision.
Inovio Pharmaceuticals (INO) Company Overview
Inovio Pharmaceuticals is a clinical-stage biotechnology company focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases. Its platform pairs precisely designed DNA plasmids with the proprietary CELLECTRA electroporation device to deliver genetic material into cells without relying on viral vectors or lipid nanoparticles.
The lead program, INO-3107, targets recurrent respiratory papillomatosis, a rare chronic condition driven by HPV types 6 and 11. The company is also advancing VGX-3100 for HPV-related cervical dysplasia under a license to ApolloBio for Greater China, along with next-generation DNA-encoded monoclonal antibody programs. With no approved products on the market, INO functions largely as a binary, event-driven investment tied to regulatory milestones rather than current revenue.
INO Stock Performance: 30 Days Versus the Quarter
Over the last 30 days, INO advanced approximately 105%, moving from a closing level near $0.66 to roughly $1.36. Most of the gain came after a late-July low near $0.57 as the stock reversed higher through August. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The three-month view shows more volatility. The stock started near $1.14 in early June, touched the low $1.20s in early July, then dropped sharply after the financing news before recovering to a net gain of roughly 19% for the quarter. Even with the rebound, shares sit well below the 52-week high of approximately $2.98.
What Fueled the Recent 30-Day Rally
The main driver was recovery from a dilution-driven selloff. On July 29, 2026, Inovio announced a $20 million public offering at $0.95 per share with attached warrants, pushing the stock down to around $0.656 by July 30. Positive follow-through news then supported the rebound.
On August 12, the company reported second-quarter 2026 results with a net loss of $6.0 million, or $0.07 per share, compared with $23.5 million, or $0.61 per share, a year earlier. Management noted that the FDA had completed its late-cycle review meeting and pre-licensure inspections for INO-3107, keeping the October 30, 2026 PDUFA date on track. The next day, Jefferies upgraded the stock to Buy with a $3.00 price target, while H.C. Wainwright kept a Neutral rating and $2.50 target. These updates helped lift a volatile small-cap name with elevated short interest.
Broader Quarterly Developments
The quarter centered on progress toward a potential first commercial launch. The FDA accepted the Biologics License Application for INO-3107 under the accelerated approval pathway in December 2025, setting the October 30, 2026 PDUFA date. Key review milestones, including pre-licensure inspections and clinical meetings, were completed during the period.
The July offering raised about $18.3 million in net proceeds, extending the cash runway into late first-quarter 2027 and through a possible launch. While the financing weighed on the stock near term, it eased immediate liquidity concerns. Positive Phase 3 topline results for VGX-3100 from partner ApolloBio in China also reinforced the broader DNA-medicine platform.
Key Catalysts to Watch
The most important near-term event remains the FDA decision on INO-3107 with its October 30, 2026 PDUFA target action date. Investors will focus on the agency’s stance on accelerated approval eligibility, confirmatory trial feedback, and label negotiations that could begin in September. Commercial preparation through Syneos Health and competition from the approved therapy Papzimeos also merit attention. The current cash runway reaches into late first-quarter 2027, though additional financing could still be needed depending on launch timing. Longer-term pipeline updates, including a potential VGX-3100 filing in China, add further context.
Monitoring Biotech Volatility with AI Tools
I often turn to Tickeron’s AI Trading Bots when tracking high-volatility names like this one. The platform offers a range of automated strategies across thousands of tickers, letting users compare different approaches based on their own risk tolerance and time horizons. Exploring the curated selection of top-performing bots provides a practical way to stay on top of momentum signals without constant manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INO in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 14, 2026
INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 43 cases where INO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 59 cases where INO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 183 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 122 of 159 cases where INO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 14 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 65 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for INO turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 38 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.701) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology
Advertisement